The disclosure section in the cited research article may indicate a financial interest in the authors being able to say that Prozac is not effective:
“ MAH and JM are co-applicants on the RELEASE and RELEASE + trials in Australia, funded by the Medical Research Future Fund (MRFF) and the National Health and Medical Research Council (NHMRC), evaluating hyperbolic tapering of antidepressants against care as usual. MAH reports being a co-founder of and consultant to Outro Health, a digital clinic which provides support for patients in the US to help stop no longer needed antidepressant treatment using gradual, hyperbolic tapering; and receives royalties for the Maudsley Deprescribing Guidelines. JM receives royalties for books about psychiatric drugs, and was a co-applicant on the REDUCE trial, funded by the National Institute of Health Research, evaluating digital support for patients stopping long-term antidepressant treatment. MP and RL have no conflicts of interest to declare.”
I would caution those in this thread who have never seen or treated patients in any psychiatric clinic or hospital let alone a pediatric one to be careful assuming that they have adequate experience to make sweeping judgements on the utility of antidepressants in children.
Maybe, but I think more likely is the time factor for med students. There’s really only time to find the major structures implicated in disease. Surgeons also not likely dissecting around the clitoris much. Wouldn’t want to risk injury obviously.
Strong work. Looking forward to / dreading the update with the 2023 and 2024 data that I've been more involved with. RIP to all of the young people in their late teens and 20s who made the mistake of using a road for anything other than driving. RIP to the older folks who got smoked just crossing the street. RIP to everyone else who didn't deserve to go. Hopefully there is traffic calming and reliable, frequent public transit in heaven.
Unfortunately this dataset doesn't include the, probably more frequent, severe TBIs. Surely wouldn't take many patients for the cost of a hemicraniectomy, 2 week neuro-ICU stay, trach/peg, and long term acute care stay to equal the cost of a few measures to slow drivers down. Not to mention lost earning/tax potential. Too bad it's not from the same budget.
Wear your seatbelt and a helmet and hopefully you can avoid the pain of your family having to have a surprise end-of-life discussion with me.
“ MAH and JM are co-applicants on the RELEASE and RELEASE + trials in Australia, funded by the Medical Research Future Fund (MRFF) and the National Health and Medical Research Council (NHMRC), evaluating hyperbolic tapering of antidepressants against care as usual. MAH reports being a co-founder of and consultant to Outro Health, a digital clinic which provides support for patients in the US to help stop no longer needed antidepressant treatment using gradual, hyperbolic tapering; and receives royalties for the Maudsley Deprescribing Guidelines. JM receives royalties for books about psychiatric drugs, and was a co-applicant on the REDUCE trial, funded by the National Institute of Health Research, evaluating digital support for patients stopping long-term antidepressant treatment. MP and RL have no conflicts of interest to declare.”
I would caution those in this thread who have never seen or treated patients in any psychiatric clinic or hospital let alone a pediatric one to be careful assuming that they have adequate experience to make sweeping judgements on the utility of antidepressants in children.